Overview Dividends

(INGN) Inogen - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45780L1044

Portable Concentrators, Stationary Concentrators, Batteries, Accessories

INGN EPS (Earnings per Share)

EPS (Earnings per Share) of INGN over the last years for every Quarter: "2020-09": -0.08, "2020-12": -0.23, "2021-03": -0.03, "2021-06": 0.22, "2021-09": 0.53, "2021-12": -1.01, "2022-03": -0.62, "2022-06": -0.15, "2022-09": -0.42, "2022-12": -0.2, "2023-03": -0.88, "2023-06": -0.42, "2023-09": -0.55, "2023-12": -1.14, "2024-03": -0.62, "2024-06": -0.24, "2024-09": -0.25, "2024-12": -0.24, "2025-03": -0.11, "2025-06": -0.15, "2025-09": 0,
EPS Growth (3Y CAGR): 7.09%
EPS Trend (3Y Correlation): 60.2%

INGN Revenue

Revenue of INGN over the last years for every Quarter: 2020-09: 74.329, 2020-12: 73.978, 2021-03: 86.932, 2021-06: 101.563, 2021-09: 93.105, 2021-12: 76.403, 2022-03: 80.385, 2022-06: 103.376, 2022-09: 105.389, 2022-12: 88.091, 2023-03: 72.162, 2023-06: 83.635, 2023-09: 83.967, 2023-12: 75.896, 2024-03: 78.025, 2024-06: 88.765, 2024-09: 88.834, 2024-12: 80.081, 2025-03: 82.28, 2025-06: 92.277, 2025-09: null,
Revenue Growth (3Y CAGR): -4.72%
Revenue Trend (3Y Correlation): -10.7%

Description: INGN Inogen October 29, 2025

Inogen, Inc. (NASDAQ: INGN) designs, manufactures, and markets portable and stationary oxygen-concentrator systems for long-term oxygen therapy (LTOT) in the United States and abroad. Its product line includes the Inogen One and Inogen Rove ambulatory devices, the Rove 4 portable concentrator, the Inogen At Home stationary unit, the Simeox airway-clearance system, batteries, and accessories, with a rental-to-patient model that supplements direct sales.

Key operating metrics (2023 FY) show revenue of roughly $210 million, a net loss of $30 million, and cash and equivalents of $120 million, giving the company an estimated 12-month cash runway under current burn-rate assumptions. Growth drivers include the aging U.S. population (≈ 16 % over 65) and increasing outpatient LTOT utilization, while reimbursement pressure from Medicare and competition from larger OEMs such as Philips Respironics remain material risks. The broader health-care equipment sector is benefiting from a shift toward home-based care, which historically adds a 4-6 % premium to valuation multiples for companies with proven distribution networks.

For a deeper, data-driven valuation framework, you might explore the Inogen profile on ValueRay.

INGN Stock Overview

Market Cap in USD 223m
Sub-Industry Health Care Equipment
IPO / Inception 2014-02-14

INGN Stock Ratings

Growth Rating -69.0%
Fundamental 27.6%
Dividend Rating -
Return 12m vs S&P 500 -35.2%
Analyst Rating 3.67 of 5

INGN Dividends

Currently no dividends paid

INGN Growth Ratios

Growth Correlation 3m 38.5%
Growth Correlation 12m -42.8%
Growth Correlation 5y -84.6%
CAGR 5y -32.52%
CAGR/Max DD 3y (Calmar Ratio) -0.39
CAGR/Mean DD 3y (Pain Ratio) -0.53
Sharpe Ratio 12m -1.12
Alpha -53.10
Beta 1.810
Volatility 66.43%
Current Volume 177.7k
Average Volume 20d 158.8k
Stop Loss 6.5 (-7%)
Signal -0.43

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-26.0m TTM) > 0 and > 6% of Revenue (6% = 20.6m TTM)
FCFTA -0.05 (>2.0%) and ΔFCFTA 1.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 39.61% (prev 37.53%; Δ 2.08pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.03 (>3.0%) and CFO -8.47m > Net Income -26.0m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.03 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (27.0m) change vs 12m ago 14.18% (target <= -2.0% for YES)
Gross Margin 41.84% (prev 43.63%; Δ -1.78pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 110.6% (prev 105.7%; Δ 4.89pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -3.87 (EBITDA TTM -26.6m / Interest Expense TTM -9.31m) >= 6 (WARN >= 3)

Altman Z'' -1.12

(A) 0.44 = (Total Current Assets 203.1m - Total Current Liabilities 67.1m) / Total Assets 312.0m
(B) -0.52 = Retained Earnings (Balance) -163.2m / Total Assets 312.0m
(C) -0.12 = EBIT TTM -36.0m / Avg Total Assets 310.5m
(D) -1.42 = Book Value of Equity -160.2m / Total Liabilities 112.5m
Total Rating: -1.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 27.60

1. Piotroski 1.50pt = -3.50
2. FCF Yield -13.78% = -5.0
3. FCF Margin -4.79% = -1.80
4. Debt/Equity 0.10 = 2.50
5. Debt/Ebitda 3.18 = -2.00
6. ROIC - WACC (= -30.76)% = -12.50
7. RoE -13.77% = -2.29
8. Rev. Trend -10.74% = -0.81
9. EPS Trend 60.19% = 3.01

What is the price of INGN shares?

As of November 08, 2025, the stock is trading at USD 6.99 with a total of 177,681 shares traded.
Over the past week, the price has changed by -15.17%, over one month by -18.63%, over three months by +19.08% and over the past year by -26.11%.

Is Inogen a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Inogen (NASDAQ:INGN) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 27.60 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INGN is around 4.59 USD . This means that INGN is currently overvalued and has a potential downside of -34.33%.

Is INGN a buy, sell or hold?

Inogen has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold INGN.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 0
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the INGN price?

Issuer Target Up/Down from current
Wallstreet Target Price 13 86%
Analysts Target Price 13 86%
ValueRay Target Price 5.3 -24.2%

INGN Fundamental Data Overview November 04, 2025

Market Cap USD = 222.8m (222.8m USD * 1.0 USD.USD)
P/S = 0.6487
P/B = 1.1562
P/EG = 3.48
Beta = 1.81
Revenue TTM = 343.5m USD
EBIT TTM = -36.0m USD
EBITDA TTM = -26.6m USD
Long Term Debt = 19.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.08m USD (from shortTermDebt, last quarter)
Debt = 19.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -84.6m USD (from netDebt column, last quarter)
Enterprise Value = 119.4m USD (222.8m + Debt 19.0m - CCE 122.4m)
Interest Coverage Ratio = -3.87 (Ebit TTM -36.0m / Interest Expense TTM -9.31m)
FCF Yield = -13.78% (FCF TTM -16.5m / Enterprise Value 119.4m)
FCF Margin = -4.79% (FCF TTM -16.5m / Revenue TTM 343.5m)
Net Margin = -7.58% (Net Income TTM -26.0m / Revenue TTM 343.5m)
Gross Margin = 41.84% ((Revenue TTM 343.5m - Cost of Revenue TTM 199.7m) / Revenue TTM)
Gross Margin QoQ = 38.69% (prev 36.93%)
Tobins Q-Ratio = 0.38 (Enterprise Value 119.4m / Total Assets 312.0m)
Interest Expense / Debt = 9.26% (Interest Expense 1.76m / Debt 19.0m)
Taxrate = 3.55% (-153.0k / -4.30m)
NOPAT = -34.8m (EBIT -36.0m * (1 - 3.55%)) [loss with tax shield]
Current Ratio = 3.03 (Total Current Assets 203.1m / Total Current Liabilities 67.1m)
Debt / Equity = 0.10 (Debt 19.0m / totalStockholderEquity, last quarter 199.5m)
Debt / EBITDA = 3.18 (negative EBITDA) (Net Debt -84.6m / EBITDA -26.6m)
Debt / FCF = 5.14 (negative FCF - burning cash) (Net Debt -84.6m / FCF TTM -16.5m)
Total Stockholder Equity = 189.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.35% (Net Income -26.0m / Total Assets 312.0m)
RoE = -13.77% (Net Income TTM -26.0m / Total Stockholder Equity 189.2m)
RoCE = -17.31% (EBIT -36.0m / Capital Employed (Equity 189.2m + L.T.Debt 19.0m))
RoIC = -18.37% (negative operating profit) (NOPAT -34.8m / Invested Capital 189.2m)
WACC = 12.38% (E(222.8m)/V(241.8m) * Re(12.68%) + D(19.0m)/V(241.8m) * Rd(9.26%) * (1-Tc(0.04)))
Discount Rate = 12.68% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.54%
Fair Price DCF = unknown (Cash Flow -16.5m)
EPS Correlation: 60.19 | EPS CAGR: 7.09% | SUE: 0.80 | # QB: 0
Revenue Correlation: -10.74 | Revenue CAGR: -4.72% | SUE: 0.34 | # QB: 0

Additional Sources for INGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle